Clovis Oncology, Inc. (CLVS)
-NasdaqGS 35.19 
0.43(1.21%) 4:00PM EDT
| Prev Close: | 35.62 |
|---|
| Open: | 35.38 |
|---|
| Bid: | 26.50 x 100 |
|---|
| Ask: | 37.00 x 100 |
|---|
| 1y Target Est: | 45.25 |
|---|
| Beta: | 4.426 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 35.05 - 36.11 |
|---|
| 52wk Range: | 11.19 - 40.27 |
|---|
| Volume: | 73,147 |
|---|
| Avg Vol (3m): | 150,481 |
|---|
| Market Cap: | 924.27M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.73 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue 10:11AM EDT)
- May 2013 IPO Market Updateat Seeking Alpha(Sun, May 19)
- Clovis Oncology says data to be presented at ASCO annual meetingtheflyonthewall.com(Thu, May 16)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- CLOVIS ONCOLOGY, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- 4 Stocks Rising on Unusual Volumeat TheStreet(Wed, May 8)
- Clovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las VegasBusiness Wire(Wed, May 8)
- CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Clovis Oncology's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Clovis Oncology, Inc. Earnings Call scheduled for 8:30 am ET todayCCBN(Tue, May 7)
- Q1 2013 Clovis Oncology, Inc. Earnings Release - Before Market OpenCCBN(Tue, May 7)
- Clovis Oncology Announces First Quarter 2013 Operating ResultsBusiness Wire(Tue, May 7)
- CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhEDGAR Online(Tue, May 7)
- Understanding the Clinical-Development Pathway Required by the FDA and EMA: An Expert Analyst Discusses His Strategy in Investing in Biotech StocksWall Street Transcript(Mon, Apr 29)
- The Best- And Worst-Performing Biotech Stocks, April 19 to April 26at Forbes(Sat, Apr 27)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.78 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.69 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
View More